Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703

April 7, 2021 – Seattle, AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical
study (NCT04329728 “The WWRD Study”).